Companies Theravance Biopharma, Inc.
Theravance Biopharma (TBPH): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Theravance Biopharma, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $4,318,531FY2023
- $3,995,931FY2024
- $1,472,019FY2025
CEO total pay was $1,472,019 in fiscal 2025, down from $3,995,931 in fiscal 2024.
FY2025: salary $1,047,431 · bonus $0 · stock awards $0 · option awards $0
Executives and directors
Aine Miller · SVPRhonda Farnum · SVPRick Winningham · CEODean J. Mitchell · Independent DirectorDeepika R. Pakianathan, Ph.D · Independent DirectorDonal O'Connor · DirectorEran Broshy · Independent DirectorJames Kelly · Independent DirectorJeremy T. Grant · Independent DirectorLaurie Smaldone Alsup, M.D · Independent DirectorSusannah Gray · Chair of the Board
Frequently asked questions
Who was the highest-paid executive at Theravance Biopharma, Inc. in fiscal 2025?
As disclosed, Rick Winningham (Chief Executive Officer) was the highest-paid executive at Theravance Biopharma, Inc. in fiscal 2025, with total compensation of $1,472,019.
How did shareholders vote on Theravance Biopharma, Inc.'s executive compensation?
As disclosed, 99.48% of shareholders supported Theravance Biopharma, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Theravance Biopharma, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Theravance Biopharma, Inc. reported total board compensation of $1,365,814 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Rick Winningham | $1,047,431 | $0 | $0 | $0 | $419,182 | $0 | $5,406 | $1,472,019 |
| Chief Executive Officer | ||||||||
| Aine Miller | 506,225 | 0 | 701,250 | 0 | 169,962 | 0 | 71,135 | 1,448,573 |
| Senior Vice President, Development and Head of Ireland Office | ||||||||
| Rhonda Farnum | 506,303 | 0 | 701,250 | 0 | 169,263 | 0 | 7,376 | 1,384,192 |
| Chief Business Officer and Senior Vice President, Commercial & Medical Affairs | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Rick Winningham | $1,472,019 | $3,995,931 | $4,318,531 | ↓ −2,523,912 |
| Aine Miller | 1,448,573 | — | — | — |
| Rhonda Farnum | 1,384,192 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our goal is to maintain a compensation program that will fairly compensate employees while attracting and retaining highly qualified employees, motivating their performance and rewarding the achievement of key corporate goals. We also aim to align employees long-term interests with those of our shareholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Frederic W. Cook & Co. (FW Cook) |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Aine Miller | RSA | — | — | — | — | — | $701,250 |
| Rhonda Farnum | RSA | — | — | — | — | — | 701,250 |
Vehicle mix — grant-date fair value by award type
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Aine Miller | RSU | 2,187 | — | $40,919 |
| Rhonda Farnum | RSU | 2,642 | — | 49,432 |
| Aine Miller | RSU | 5,215 | — | 97,572 |
| Rhonda Farnum | PSU | 6,250 | — | 116,938 |
| Aine Miller | PSU | 9,375 | — | 175,406 |
| Rick Winningham | RSU | 10,625 | — | 198,794 |
| Aine Miller | RSU | 13,281 | — | 248,488 |
| Aine Miller | RSU | 18,750 | — | 350,813 |
| Aine Miller | RSU | 21,094 | — | 394,668 |
| Rhonda Farnum | RSU | 21,094 | — | 394,669 |
| Rick Winningham | Option | 21,458 | 10.24 | — |
| Rhonda Farnum | RSU | 23,437 | — | 438,506 |
| Rick Winningham | RSU | 34,368 | — | 643,025 |
| Rick Winningham | RSU | 51,562 | — | 964,725 |
| Rick Winningham | PSU | 55,000 | — | 1,029,050 |
| Rhonda Farnum | RSU | 75,000 | — | 1,403,250 |
| Aine Miller | RSU | 75,000 | — | 1,403,250 |
| Rick Winningham | RSU | 84,375 | — | 1,587,656 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Susannah GrayIndependent · Board Chair · Audit · Strategic Review Committee (Chair) | $123,356 | $99,994 | $124,929 | — | $0 | $348,279 |
| Donal O'Connor | 95,000 | 99,994 | 124,929 | — | 0 | 319,923 |
| Deepika R. Pakianathan, Ph.DIndependent · Audit · Nominating/Governance (Chair) · Development and Commercialization Committee · Strategic Review Committee | 92,500 | 99,994 | 124,929 | — | 0 | 317,423 |
| Eran BroshyIndependent · Audit · Compensation (Chair) | 81,000 | 99,994 | 124,929 | — | 0 | 305,923 |
| Dean J. MitchellIndependent · Compensation · Development and Commercialization Committee · Strategic Review Committee | 80,000 | 99,994 | 124,929 | — | 0 | 304,923 |
| Jeremy T. GrantIndependent · Compensation · Development and Commercialization Committee · Strategic Review Committee | 72,500 | 99,994 | 124,929 | — | 0 | 297,423 |
| Laurie Smaldone Alsup, M.DIndependent · Nominating/Governance · Development and Commercialization Committee (Chair) | 66,500 | 99,994 | 124,929 | — | 0 | 291,423 |
| James KellyIndependent · Nominating/Governance | 55,000 | 0 | 0 | — | 0 | 55,000 |
| Rick E WinninghamEmployee director · Development and Commercialization Committee | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $100,000 |
| Per board meeting fee | $1,500 |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | $250,000 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $665,856 |
| Equity awards (grant-date value) | $699,958 |
| All other compensation | $0 |
| Total cost of the board | $1,365,814 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Theravance Biopharma as a peer
Companies that benchmark against TBPH
5 companies name TBPH as a compensation peer
- Akebia Therapeutics, Inc.AKBAFY2025
- Innoviva, Inc.INVAFY2025
- Liquidia CorpLQDAFY2025
- RIGEL PHARMACEUTICALS INCRIGLFY2025
- SIGA TECHNOLOGIES INCSIGAFY2025
Each company listed discloses TBPH in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TBPH in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Theravance Biopharma, Inc. | 2025 | Rick Winningham | $1,047,431 | $0 | $0 | $419,182 | $1,472,019 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-12 | 42,631,324 | 221,196 | 51,183 | 99.48% | Passed |
| 2025 | 2025-05-19 | 30,154,992 | 374,257 | 9,536,311 | 98.77% | Passed |
| 2024 | 2024-05-08 | 35,205,714 | 332,345 | 2,683 | 99.06% | Passed |
| 2023 | 2023-05-02 | 42,597,635 | 5,073,854 | 45,307 | 89.36% | Passed |
| 2020 | 2020-04-28 | 50,181,713 | 357,544 | 30,952 | 99.29% | Passed |
| 2017 | 2017-05-17 | 46,846,621 | 1,072,055 | 146,741 | 97.76% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-12 | 99.48%a |
| 2025 | 2025-05-19 | 98.77%b |
| 2024 | 2024-05-08 | 99.06%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not affect the outcome of Proposal One, other than counting towards the quorum of the meeting.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not affect the outcome of Proposal One, other than counting towards the quorum of the meeting.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not affect the outcome of Proposal One, other than counting towards the quorum of the meeting.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Rhonda Farnum | SVP, Comm & Medical Affairs | 2026-05-20 | D | 5,678 | $17 | $93,971 | Common | Form 4 ↗ |
| Aziz Sawaf | SVP & Chief Financial Officer | 2026-05-20 | D | 8,670 | 17 | 143,489 | Common | Form 4 ↗ |
| Brett A. Grimaud | SVP, Gen Counsel and Secretary | 2026-05-20 | D | 8,829 | 17 | 146,120 | Common | Form 4 ↗ |
| Rick E. Winningham | Director | 2026-05-20 | D | 20,038 | 17 | 331,629 | Common | Form 4 ↗ |
| Aine Miller | SVP, Dev & Head of IRE Office | 2026-05-20 | D | 6,827 | 17 | 112,987 | Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-06-12 | A | 13,398 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donal O'Connor | Director | 2026-06-12 | A | 6,009 | 0 | 0 | Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-06-12 | A | 6,009 | 0 | 0 | Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-06-12 | A | 6,009 | 0 | 0 | Common | Form 4 ↗ |
| Deepika Pakianathan | Director | 2026-06-12 | A | 6,009 | 0 | 0 | Common | Form 4 ↗ |
| Susannah Gray | Director | 2026-06-12 | A | 6,009 | 0 | 0 | Common | Form 4 ↗ |
| Donal O'Connor | Director | 2026-06-12 | A | 13,398 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-06-12 | A | 13,398 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Deepika Pakianathan | Director | 2026-06-12 | A | 13,398 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susannah Gray | Director | 2026-06-12 | A | 13,398 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rhonda Farnum | SVP, Comm & Medical Affairs | 2026-06-15 | D | 6,657 | 16 | 109,079 | Common, open-market sale | Form 4 ↗ |
| Rhonda Farnum | SVP, Comm & Medical Affairs | 2026-06-15 | D | 3,329 | 16 | 54,563 | Common, open-market sale | Form 4 ↗ |
| Rhonda Farnum | SVP, Comm & Medical Affairs | 2026-06-15 | D | 3,328 | 16 | 54,525 | Common, open-market sale | Form 4 ↗ |
| Aine Miller | SVP, Dev & Head of IRE Office | 2026-06-19 | A | 18,750 | 0 | 0 | Common | Form 4 ↗ |
| Eli Samaha | Greater-than-10% holder | 2026-06-29 | D | 273,871 | 17 | 4,720,139 | Common, indirect | Form 4 ↗ |
| Eli Samaha | Greater-than-10% holder | 2026-06-30 | D | 25,027 | 17 | 428,788 | Common, indirect | Form 4 ↗ |
| Eli Samaha | Greater-than-10% holder | 2026-07-01 | D | 37,799 | 17 | 642,628 | Common, indirect | Form 4 ↗ |
| Eli Samaha | Greater-than-10% holder | 2026-07-06 | D | 1,400 | 17 | 23,856 | Common, indirect | Form 4 ↗ |
| Eli Samaha | Greater-than-10% holder | 2026-07-07 | D | 5,564 | 17 | 95,541 | Common, indirect | Form 4 ↗ |
| Aine Miller | SVP, Dev & Head of IRE Office | 2026-08-20 | D | 6,258 | 17 | 106,073 | Common | Form 4 ↗ |
| Brett A. Grimaud | SVP, Gen Counsel and Secretary | 2026-08-20 | D | 7,952 | 17 | 134,786 | Common | Form 4 ↗ |
| Rhonda Farnum | SVP, Comm & Medical Affairs | 2026-08-20 | D | 5,667 | 17 | 96,056 | Common | Form 4 ↗ |
| Rick E. Winningham | Director | 2026-08-20 | D | 20,034 | 17 | 339,576 | Common | Form 4 ↗ |
| Aziz Sawaf | SVP & Chief Financial Officer | 2026-08-20 | D | 8,112 | 17 | 137,498 | Common | Form 4 ↗ |
| Rhonda Farnum | SVP, Comm & Medical Affairs | 2026-09-15 | D | 6,657 | 17 | 113,397 | Common, open-market sale | Form 4 ↗ |
| Rhonda Farnum | SVP, Comm & Medical Affairs | 2026-09-15 | D | 3,328 | 17 | 56,690 | Common, open-market sale | Form 4 ↗ |
| Rhonda Farnum | SVP, Comm & Medical Affairs | 2026-09-15 | D | 3,329 | 17 | 56,707 | Common, open-market sale | Form 4 ↗ |
| Donal O'Connor | Director | 2026-09-23 | D | 13,398 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donal O'Connor | Director | 2026-09-23 | D | 24,258 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donal O'Connor | Director | 2026-09-23 | D | 23,576 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donal O'Connor | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donal O'Connor | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donal O'Connor | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donal O'Connor | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donal O'Connor | Director | 2026-09-23 | D | 74,204 | — | — | Common | Form 4 ↗ |
| Rick E. Winningham | Director | 2026-09-23 | D | 515,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Rick E. Winningham | Director | 2026-09-23 | D | 92,567 | — | — | Common | Form 4 ↗ |
| Rick E. Winningham | Director | 2026-09-23 | D | 23,400 | — | — | Common | Form 4 ↗ |
| Rick E. Winningham | Director | 2026-09-23 | D | 76,875 | — | — | Common | Form 4 ↗ |
| Rick E. Winningham | Director | 2026-09-23 | D | 151,875 | — | — | Common | Form 4 ↗ |
| Rick E. Winningham | Director | 2026-09-23 | D | 1,382,272 | — | — | Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-09-23 | D | 24,258 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-09-23 | D | 23,576 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-09-23 | D | 22,044 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-09-23 | D | 28,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-09-23 | D | 13,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-09-23 | D | 6,009 | — | — | Common | Form 4 ↗ |
| Deepika Pakianathan | Director | 2026-09-23 | D | 13,398 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deepika Pakianathan | Director | 2026-09-23 | D | 24,258 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deepika Pakianathan | Director | 2026-09-23 | D | 23,576 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deepika Pakianathan | Director | 2026-09-23 | D | 22,044 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deepika Pakianathan | Director | 2026-09-23 | D | 28,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deepika Pakianathan | Director | 2026-09-23 | D | 17,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deepika Pakianathan | Director | 2026-09-23 | D | 6,009 | — | — | Common | Form 4 ↗ |
| Deepika Pakianathan | Director | 2026-09-23 | D | 58,065 | — | — | Common | Form 4 ↗ |
| Brett A. Grimaud | SVP, Gen Counsel and Secretary | 2026-09-23 | D | 223,917 | — | — | Common | Form 4 ↗ |
| Susannah Gray | Director | 2026-09-23 | D | 23,576 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susannah Gray | Director | 2026-09-23 | D | 22,044 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susannah Gray | Director | 2026-09-23 | D | 6,009 | — | — | Common | Form 4 ↗ |
| Susannah Gray | Director | 2026-09-23 | D | 42,137 | — | — | Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-09-23 | D | 13,398 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-09-23 | D | 24,258 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-09-23 | D | 23,576 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-09-23 | D | 22,044 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-09-23 | D | 28,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-09-23 | D | 6,009 | — | — | Common | Form 4 ↗ |
| Aziz Sawaf | SVP & Chief Financial Officer | 2026-09-23 | D | 23,439 | — | — | Common | Form 4 ↗ |
| Aziz Sawaf | SVP & Chief Financial Officer | 2026-09-23 | D | 108,436 | — | — | Common | Form 4 ↗ |
| Aziz Sawaf | SVP & Chief Financial Officer | 2026-09-23 | D | 204,966 | — | — | Common | Form 4 ↗ |
| Rhonda Farnum | SVP, Comm & Medical Affairs | 2026-09-23 | D | 89,062 | — | — | Common | Form 4 ↗ |
| Rhonda Farnum | SVP, Comm & Medical Affairs | 2026-09-23 | D | 124,414 | — | — | Common | Form 4 ↗ |
| Rhonda Farnum | SVP, Comm & Medical Affairs | 2026-09-23 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-09-23 | D | 13,398 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brett A. Grimaud | SVP, Gen Counsel and Secretary | 2026-09-23 | D | 23,439 | — | — | Common | Form 4 ↗ |
| Aine Miller | SVP, Dev & Head of IRE Office | 2026-09-23 | D | 93,108 | — | — | Common | Form 4 ↗ |
| Weiss Asset Management LP | — | 2026-09-23 | D | 7,457,060 | 17 | 126,770,020 | Common | Form 4 ↗ |
| Brett A. Grimaud | SVP, Gen Counsel and Secretary | 2026-09-23 | D | 107,812 | — | — | Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alsup Laurie Smaldone | Director | 2026-09-23 | D | 74,980 | — | — | Common | Form 4 ↗ |
| Susannah Gray | Director | 2026-09-23 | D | 32,666 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donal O'Connor | Director | 2026-09-23 | D | 22,044 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donal O'Connor | Director | 2026-09-23 | D | 28,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Donal O'Connor | Director | 2026-09-23 | D | 6,009 | — | — | Common | Form 4 ↗ |
| Aine Miller | SVP, Dev & Head of IRE Office | 2026-09-23 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aine Miller | SVP, Dev & Head of IRE Office | 2026-09-23 | D | 96,718 | — | — | Common | Form 4 ↗ |
| Susannah Gray | Director | 2026-09-23 | D | 13,398 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susannah Gray | Director | 2026-09-23 | D | 24,258 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dean J. Mitchell | Director | 2026-09-23 | D | 91,204 | — | — | Common | Form 4 ↗ |
| Deepika Pakianathan | Director | 2026-09-23 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (122 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Rick Winningham. DEF 14A, filed 2026-04-28. Section “2025 Summary Compensation Table” · page 32. As printed: 1,472,019. View filing ↗
- Section 01, Aine Miller. DEF 14A, filed 2026-04-28. Section “2025 Summary Compensation Table” · page 32. As printed: 1,448,573. View filing ↗
- Section 01, Rhonda Farnum. DEF 14A, filed 2026-04-28. Section “2025 Summary Compensation Table” · page 32. As printed: 1,384,192. View filing ↗
- Section 03, Aine Miller RSA. DEF 14A, filed 2026-04-28. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Rhonda Farnum RSA. DEF 14A, filed 2026-04-28. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-23. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Susannah Gray. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 348,279. View filing ↗
- Section 08, Donal O'Connor. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 319,923. View filing ↗
- Section 08, Deepika R. Pakianathan, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 317,423. View filing ↗
- Section 08, Eran Broshy. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 305,923. View filing ↗
- Section 08, Dean J. Mitchell. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 304,923. View filing ↗
- Section 08, Jeremy T. Grant. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 297,423. View filing ↗
- Section 08, Laurie Smaldone Alsup, M.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 291,423. View filing ↗
- Section 08, James Kelly. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 55,000. View filing ↗
- Section 08, Rick E Winningham. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Rhonda Farnum 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aziz Sawaf 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett A. Grimaud 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rick E. Winningham 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aine Miller 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepika Pakianathan 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susannah Gray 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepika Pakianathan 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susannah Gray 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rhonda Farnum 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rhonda Farnum 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rhonda Farnum 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aine Miller 2026-06-19. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eli Samaha 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eli Samaha 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eli Samaha 2026-07-01. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eli Samaha 2026-07-06. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eli Samaha 2026-07-07. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aine Miller 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett A. Grimaud 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rhonda Farnum 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rick E. Winningham 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aziz Sawaf 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rhonda Farnum 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rhonda Farnum 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rhonda Farnum 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rick E. Winningham 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rick E. Winningham 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rick E. Winningham 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rick E. Winningham 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rick E. Winningham 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rick E. Winningham 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepika Pakianathan 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepika Pakianathan 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepika Pakianathan 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepika Pakianathan 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepika Pakianathan 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepika Pakianathan 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepika Pakianathan 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepika Pakianathan 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett A. Grimaud 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susannah Gray 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susannah Gray 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susannah Gray 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susannah Gray 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aziz Sawaf 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aziz Sawaf 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aziz Sawaf 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rhonda Farnum 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rhonda Farnum 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rhonda Farnum 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett A. Grimaud 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aine Miller 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Weiss Asset Management LP 2026-09-23. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett A. Grimaud 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alsup Laurie Smaldone 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susannah Gray 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donal O'Connor 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aine Miller 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aine Miller 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susannah Gray 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susannah Gray 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean J. Mitchell 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepika Pakianathan 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: 99.48% (votes for as printed: 42,631,324). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-20. Item 5.07 · say-on-pay result. As reported: 98.77% (votes for as printed: 30,154,992). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-09. Item 5.07 · say-on-pay result. As reported: 99.06% (votes for as printed: 35,205,714). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 665,856 + equity 699,958 + all other 0 = 1,365,814, summed across the director compensation table rows.
- Theravance Biopharma, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Theravance Biopharma, Inc.'s own proxy. As printed: 1,472,019. View filing ↗